Carlsmed

Carlsmed ROE

The Return on Equity (ROE) of Carlsmed (CARL) as of Oct 20, 2026 is -194.16 %. In the previous year, Return on Equity (ROE) was 1,373.90 % — a change of -114.13% (lower).

ROE

-194.16 %

YoY

-114.13%

Last updated:

In 2024, Carlsmed's return on equity (ROE) was -194.16 %, a -114.13% increase from the 1,373.90 % ROE in the previous year.

The Carlsmed ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2023
1,373.90 USD
Jan 1, 2024
-194.16 USD
The Carlsmed ROE history
YEARROEYoY
-194.16 %-114.13%
1,373.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Carlsmed Stock analysis

What does Carlsmed do? Carlsmed, Inc. generates revenue through its aprevo technology platform, which provides AI-based solutions for the surgical workflow. The platform includes pre-operative AI-enabled planning software that uses diagnostic imaging and algorithms to create personalized surgical plans and design aprevo interbody implants. Intra-operative advanced visualization tools support precision placement of these implants, while post-operative data collection offers insights to refine future planning. The company targets medical professionals and hospitals in the United States, focusing on lumbar interbody fusion procedures. Its products are sold under the aprevo brand, with the platform available in the U.S. market for surgical planning and implant design. Carlsmed's revenue streams come from the commercial sale of its aprevo technology platform, which integrates pre-operative planning, intra-operative visualization, and post-operative data analytics. The platform is specifically designed for lumbar interbody fusion procedures, addressing the needs of healthcare providers seeking to enhance surgical precision and outcomes. By leveraging AI-driven tools, Carlsmed enables personalized implant design and real-world data collection to improve surgical planning processes. The company's offerings are marketed to hospitals and surgeons in the U.S. healthcare sector, emphasizing the aprevo brand's role in digital surgical planning. The aprevo technology platform serves as Carlsmed's core product, offering a comprehensive solution for surgical workflows. Its pre-operative software utilizes standard-of-care imaging and AI algorithms to develop patient-specific plans and implant designs. Intra-operative tools provide advanced visualization for precise implant placement, while post-operative data collection informs continuous improvement of the planning process. The platform is indicated for use in lumbar interbody fusion procedures and is commercially available in the United States, targeting healthcare institutions that prioritize AI-enhanced surgical planning and outcomes. Carlsmed is one of the most popular companies on Eulerpool.

ROE Details

Decoding Carlsmed's Return on Equity (ROE)

Carlsmed's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Carlsmed's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Carlsmed's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Carlsmed’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Carlsmed stock

Return on Equity (ROE) of Carlsmed is -194.16 % in 2024.

Return on Equity (ROE) of Carlsmed changed from 1,373.90 % to -194.16 %, representing a -114.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Carlsmed since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Carlsmed with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Carlsmed

All Key Metrics — Carlsmed